Ellington CL, Goodman M, Kono SA, Grist W, Wadsworth T, Chen AY, et al. Adenoid cystic carcinoma of the head and neck: incidence and survival trends based on 1973–2007 surveillance, epidemiology, and end results data. Cancer. 2012;118:4444–51.

Article  PubMed  Google Scholar 

Lorini L, Ardighieri L, Bozzola A, Romani C, Bignotti E, Buglione M, et al. Prognosis and management of recurrent and/or metastatic head and neck adenoid cystic carcinoma. Oral Oncol. 2021;115:105213.

Article  CAS  PubMed  Google Scholar 

Laurie SA, Ho AL, Fury MG, Sherman E, Pfister DG. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. Lancet Oncol. 2011;12:815–24.

Article  CAS  PubMed  Google Scholar 

Kang EJ, Ahn MJ, Ock CY, Lee KW, Kwon JH, Yang Y, et al. Randomized phase II study of axitinib versus observation in patients with recurred or metastatic adenoid cystic carcinoma. Clin Cancer Res. 2021;27:5272–9.

Article  CAS  PubMed  Google Scholar 

Jones W, Griffiths K, Barata PC, Paller CJ. PSMA theranostics: review of the current status of PSMA-targeted imaging and radioligand therapy. Cancers (Basel). 2020. https://doi.org/10.3390/cancers12061367.

Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091–103.

Article  CAS  PubMed  PubMed Central  Google Scholar 

de Keizer B, Krijger GC, Ververs FT, van Es RJJ, de Bree R, Willems S. (68)Ga-PSMA PET-CT imaging of metastatic adenoid cystic carcinoma. Nucl Med Mol Imaging. 2017;51:360–1.

Article  PubMed  Google Scholar 

Klein Nulent TJW, van Es RJJ, Krijger GC, de Bree R, Willems SM, de Keizer B. Prostate-specific membrane antigen PET imaging and immunohistochemistry in adenoid cystic carcinoma-a preliminary analysis. Eur J Nucl Med Mol Imaging. 2017;44:1614–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Konig L, Hauswald H, Flechtenmacher C, Heller M, Debus J, Haberkorn U, et al. Uptake of prostate-specific membrane antigen (PSMA) in adenoid cystic carcinoma - Is PSMA-PET-CT a helpful tool in radiation oncology? Clin Transl Radiat Oncol. 2017;7:79–82.

PubMed  PubMed Central  Google Scholar 

Lutje S, Sauerwein W, Lauenstein T, Bockisch A, Poeppel TD. In vivo visualization of Prostate-Specific membrane antigen in adenoid cystic carcinoma of the salivary gland. Clin Nucl Med. 2016;41:476–7.

Article  PubMed  Google Scholar 

van Boxtel W, Lutje S, van Engen-van Grunsven ICH, Verhaegh GW, Schalken JA, Jonker MA, et al. (68)Ga-PSMA-HBED-CC PET/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study. Theranostics. 2020;10:2273–83.

Article  PubMed  PubMed Central  Google Scholar 

Klein Nulent TJW, Valstar MH, Smit LA, Smeele LE, Zuithoff NPA, de Keizer B, et al. Prostate-specific membrane antigen (PSMA) expression in adenoid cystic carcinoma of the head and neck. BMC Cancer. 2020;20:519.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oh SW, Suh M, Cheon GJ. Current status of PSMA-targeted radioligand therapy in the era of radiopharmaceutical therapy acquiring marketing authorization. Nucl Med Mol Imaging. 2022;56(6):263–81.

Article  PubMed  PubMed Central  Google Scholar 

Harsini S, Saprunoff H, Alden T, Mohammadi B, Wilson D, Benard F. The effects of monosodium glutamate on PSMA Radiotracer uptake in men with recurrent prostate cancer: A prospective, randomized, Double-Blind, Placebo-Controlled intraindividual imaging study. J Nucl Med. 2021;62:81–7.

Article  PubMed  Google Scholar 

Rousseau E, Lau J, Kuo HT, Zhang Z, Merkens H, Hundal-Jabal N, et al. Monosodium glutamate reduces (68)Ga-PSMA-11 uptake in salivary glands and kidneys in a preclinical prostate cancer model. J Nucl Med. 2018;59:1865–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rupp NJ, Umbricht CA, Pizzuto DA, Lenggenhager D, Topfer A, Muller J, et al. First clinicopathologic evidence of a non-PSMA-related uptake mechanism for (68)Ga-PSMA-11 in salivary glands. J Nucl Med. 2019;60:1270–6.

Article  CAS  PubMed  Google Scholar 

Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797–804.

Article  CAS  PubMed  Google Scholar 

Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T. [ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19:825–33.

Article  CAS  PubMed  Google Scholar 

Gafita A, Calais J, Grogan TR, Hadaschik B, Wang H, Weber M, et al. Nomograms to predict outcomes after (177)Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncol. 2021;22:1115–25.

Article  CAS  PubMed  Google Scholar 

Seifert R, Seitzer K, Herrmann K, Kessel K, Schafers M, Kleesiek J, et al. Analysis of PSMA expression and outcome in patients with advanced prostate cancer receiving (177)Lu-PSMA-617 radioligand therapy. Theranostics. 2020;10:7812–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Klein Nulent TJW, van Es RJJ, Willems SM, Braat A, Devriese LA, de Bree R, et al. First experiences with (177)Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer. EJNMMI Res. 2021;11:126.

Article  CAS  PubMed  PubMed Central  Google Scholar 

van Ruitenbeek NJ, Uijen MJM, Driessen CML, Peters SMB, Prive BM, van Engen-van Grunsven ACH, et al. Luthetisum-177-PSMA therapy for recurrent/metastatic salivary gland cancer: a prospective pilot study. Theranostics. 2024;14(14):5388–99.

Article  PubMed  PubMed Central  Google Scholar